Base Editing (ABE8e) for DDC c.1340G>A (p.Arg447His) in Aromatic L-amino acid decarboxylase deficiency

Base Editing (ABE8e) via AAV9 delivery is a rationale-driven therapeutic strategy for Aromatic L-amino acid decarboxylase deficiency targeting the DDC c.1340G>A (p.Arg447His) variant (Pathogenic, missense variant). The editing system (ABE8e-nSpCas9 (adenine base editor)) converts the pathogenic A back to G on the target strand, restoring the wild-type codon. Target tissue: CNS. Therapeutic goal: Correct/Disrupt DDC-related pathogenic alleles in striatal neurons to restore AADC activity and normalize dopamine/serotonin synthesis. Risk profile: off-target Medium (bystander bases in editing window), delivery complexity Medium, immunogenicity High (AAV pre-existing immunity).

1. Molecular basis: DDC NM_001082971.2(DDC):c.1340G>A (p.Arg447His) is classified as Pathogenic (ClinVar variation ID 2735023). Molecular consequence: missense variant. Protein change: R354H, R399H, R409H, R447H, R369H. 2. Epidemiology: Ultra-rare primary monoamine neurotransmitter disorder with only dozens to a few hundred diagnosed patients worldwide; founder variants cause higher prevalence in some East Asian populations; substantial underdiagnosis likely (WEB-03, WEB-08, PAPER-03, PAPER-06, PAPER-09). 3. Standard of care: Conventional therapy combines dopamine agonists, MAO inhibitors, pyridoxine and, occasionally, levodopa, but provides only partial and inconsistent benefit; most severely affected patients remain without head control or independent sitting and significant autonomic dysfunction (WEB-03, WEB-04, PAPER 4. Pipeline: AAV2-based intraputaminal gene replacement (eladocagene exuparvovec; Upstaza/Kebilidi) has completed Phase 1/2 and Phase 2b studies with durable motor gains and is now approved by EMA, MHRA and FDA; no in vivo gene-editing trials yet, but strong CNS AAV experience provides a template for editing vec 5. ABE clinical validation: ABE8e (Richter et al. 2020, Nat Biotechnol) achieves ~1.7x higher editing efficiency than ABE7.10. VERVE-101 demonstrated first-in-human LNP-ABE liver editing with 55-66% PCSK9 reduction (Raal et al. 2025, NEJM). Beam Therapeutics is advancing multiple ABE programs.

1. No published data specifically correcting DDC c.1340G>A (p.Arg447His) with Base Editing (ABE8e); strategy is based on general principles and must be validated preclinically.
2. PAM availability and bystander base analysis for the specific genomic context have not been performed. If no canonical NGG PAM positions the target within the editing window, PAM-flexible variants (SpRY) may be needed.
3. Delivery to CNS tissue remains a major translational bottleneck. Current vectors have limited transduction efficiency in these compartments.
4. Long-term durability, off-target genome-wide effects, and immunogenicity in the target patient population require thorough preclinical and clinical evaluation.